Overview

DHEA in Synovial Sarcoma Patients

Status:
Terminated

Trial end date:
2019-04-04

Target enrollment:

Participant gender:

Summary

DHEA is a natural allosteric inhibitor of glucose-6-phosphate dehydrogenase (G6PD). G6PD is a key regulatory enzyme for the survival of synovial sarcoma. The investigators postulate that they can inhibit the production of NADPH in synovial sarcoma and cause cell death by using a naturally occurring G6PD inhibitor.

Phase:

Phase 1

Details

Lead Sponsor:

Washington University School of Medicine

Treatments:

Dehydroepiandrosterone